Immunicum AB (STO:IMMU), a biopharmaceutical company developing therapeutic cancer vaccines, reported on Thursday a change in the number of shares and votes in the company, as a result of the implementation of a share issue with preferential rights for the company's existing shareholders.

Under this rights issue, the number of shares and votes have increased by 20,383,412, which has increased the company's share capital by SEK 1,019,170.60.

As of 31 January 2019, the total share capital in Immunicum amounts to SEK4,612,876.55 and the total number of shares and votes amount to 92,257,531.

(EUR1.00=SEK10.36)